Enterprise Financial Services Corp Grows Stock Holdings in Johnson & Johnson $JNJ

Enterprise Financial Services Corp lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,827 shares of the company’s stock after acquiring an additional 738 shares during the quarter. Enterprise Financial Services Corp’s holdings in Johnson & Johnson were worth $1,348,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. W.H. Cornerstone Investments Inc. grew its position in Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after acquiring an additional 58 shares in the last quarter. YANKCOM Partnership boosted its position in Johnson & Johnson by 0.8% in the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock valued at $1,076,000 after buying an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after acquiring an additional 60 shares in the last quarter. Ellis Investment Partners LLC increased its position in shares of Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares during the last quarter. Finally, Cypress Wealth Services LLC boosted its holdings in Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after purchasing an additional 62 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Raymond James Financial lifted their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Finally, Loop Capital set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 22nd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $203.88 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $206.94. The firm has a fifty day moving average of $188.25 and a 200-day moving average of $171.67. The company has a market cap of $491.21 billion, a price-to-earnings ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.